Cargando…

Implementation of a Rapid Multiplex Polymerase Chain Reaction Pneumonia Panel and Subsequent Antibiotic De-escalation

BACKGROUND: Net effects of implementation of a multiplex polymerase chain reaction (PCR) pneumonia panel (PNP) on antimicrobial stewardship are thus far unknown. This retrospective study evaluated the real-world impact of the PNP on time to antibiotic de-escalation in critically ill patients treated...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, Molly M, Van Schooneveld, Trevor C, Stohs, Erica J, Marcelin, Jasmine R, Alexander, Bryan T, Watkins, Andrew B, Creager, Hannah M, Bergman, Scott J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10411041/
https://www.ncbi.nlm.nih.gov/pubmed/37564742
http://dx.doi.org/10.1093/ofid/ofad382
_version_ 1785086587605876736
author Miller, Molly M
Van Schooneveld, Trevor C
Stohs, Erica J
Marcelin, Jasmine R
Alexander, Bryan T
Watkins, Andrew B
Creager, Hannah M
Bergman, Scott J
author_facet Miller, Molly M
Van Schooneveld, Trevor C
Stohs, Erica J
Marcelin, Jasmine R
Alexander, Bryan T
Watkins, Andrew B
Creager, Hannah M
Bergman, Scott J
author_sort Miller, Molly M
collection PubMed
description BACKGROUND: Net effects of implementation of a multiplex polymerase chain reaction (PCR) pneumonia panel (PNP) on antimicrobial stewardship are thus far unknown. This retrospective study evaluated the real-world impact of the PNP on time to antibiotic de-escalation in critically ill patients treated for pneumonia at an academic medical center. METHODS: This retrospective, quasi-experimental study included adult intensive care unit (ICU) patients with respiratory culture results from 1 May to 15 August 2019 (pre-PNP group) and adult ICU patients with PNP results from 1 May to 15 August 2020 (PNP group) at Nebraska Medical Center. Patients were excluded for the following reasons: any preceding positive coronavirus disease 2019 PCR test, lack of antibiotic receipt, or non–respiratory tract infection indications for antibiotics. The primary outcome was time to discontinuation of anti–methicillin-resistant Staphylococcus aureus (MRSA) therapy. Secondary outcomes included time to discontinuation of antipseudomonal therapy, frequency of early discontinuation for atypical coverage, and overall duration (in days) of antibiotic therapy for pneumonia. RESULTS: Sixty-six patients in the pre-PNP group and 58 in the PNP group were included. There were significant differences in patient characteristics between groups. The median time to anti-MRSA agent discontinuation was 49.1 hours in the pre-PNP and 41.8 hours in the PNP group (P = .28). The median time to discontinuation of antipseudomonal agents was 134.4 hours in the pre-PNP versus 98.1 hours in the PNP group (P = .47). Other outcomes were numerically but not significantly improved in our sample. CONCLUSIONS: This early look at implementation of a multiplex PNP did not demonstrate a statistically significant difference in antibiotic use but lays the groundwork to further evaluate a significant real-world impact on antibiotic de-escalation in ICU patients treated for pneumonia.
format Online
Article
Text
id pubmed-10411041
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-104110412023-08-10 Implementation of a Rapid Multiplex Polymerase Chain Reaction Pneumonia Panel and Subsequent Antibiotic De-escalation Miller, Molly M Van Schooneveld, Trevor C Stohs, Erica J Marcelin, Jasmine R Alexander, Bryan T Watkins, Andrew B Creager, Hannah M Bergman, Scott J Open Forum Infect Dis Major Article BACKGROUND: Net effects of implementation of a multiplex polymerase chain reaction (PCR) pneumonia panel (PNP) on antimicrobial stewardship are thus far unknown. This retrospective study evaluated the real-world impact of the PNP on time to antibiotic de-escalation in critically ill patients treated for pneumonia at an academic medical center. METHODS: This retrospective, quasi-experimental study included adult intensive care unit (ICU) patients with respiratory culture results from 1 May to 15 August 2019 (pre-PNP group) and adult ICU patients with PNP results from 1 May to 15 August 2020 (PNP group) at Nebraska Medical Center. Patients were excluded for the following reasons: any preceding positive coronavirus disease 2019 PCR test, lack of antibiotic receipt, or non–respiratory tract infection indications for antibiotics. The primary outcome was time to discontinuation of anti–methicillin-resistant Staphylococcus aureus (MRSA) therapy. Secondary outcomes included time to discontinuation of antipseudomonal therapy, frequency of early discontinuation for atypical coverage, and overall duration (in days) of antibiotic therapy for pneumonia. RESULTS: Sixty-six patients in the pre-PNP group and 58 in the PNP group were included. There were significant differences in patient characteristics between groups. The median time to anti-MRSA agent discontinuation was 49.1 hours in the pre-PNP and 41.8 hours in the PNP group (P = .28). The median time to discontinuation of antipseudomonal agents was 134.4 hours in the pre-PNP versus 98.1 hours in the PNP group (P = .47). Other outcomes were numerically but not significantly improved in our sample. CONCLUSIONS: This early look at implementation of a multiplex PNP did not demonstrate a statistically significant difference in antibiotic use but lays the groundwork to further evaluate a significant real-world impact on antibiotic de-escalation in ICU patients treated for pneumonia. Oxford University Press 2023-07-17 /pmc/articles/PMC10411041/ /pubmed/37564742 http://dx.doi.org/10.1093/ofid/ofad382 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Major Article
Miller, Molly M
Van Schooneveld, Trevor C
Stohs, Erica J
Marcelin, Jasmine R
Alexander, Bryan T
Watkins, Andrew B
Creager, Hannah M
Bergman, Scott J
Implementation of a Rapid Multiplex Polymerase Chain Reaction Pneumonia Panel and Subsequent Antibiotic De-escalation
title Implementation of a Rapid Multiplex Polymerase Chain Reaction Pneumonia Panel and Subsequent Antibiotic De-escalation
title_full Implementation of a Rapid Multiplex Polymerase Chain Reaction Pneumonia Panel and Subsequent Antibiotic De-escalation
title_fullStr Implementation of a Rapid Multiplex Polymerase Chain Reaction Pneumonia Panel and Subsequent Antibiotic De-escalation
title_full_unstemmed Implementation of a Rapid Multiplex Polymerase Chain Reaction Pneumonia Panel and Subsequent Antibiotic De-escalation
title_short Implementation of a Rapid Multiplex Polymerase Chain Reaction Pneumonia Panel and Subsequent Antibiotic De-escalation
title_sort implementation of a rapid multiplex polymerase chain reaction pneumonia panel and subsequent antibiotic de-escalation
topic Major Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10411041/
https://www.ncbi.nlm.nih.gov/pubmed/37564742
http://dx.doi.org/10.1093/ofid/ofad382
work_keys_str_mv AT millermollym implementationofarapidmultiplexpolymerasechainreactionpneumoniapanelandsubsequentantibioticdeescalation
AT vanschooneveldtrevorc implementationofarapidmultiplexpolymerasechainreactionpneumoniapanelandsubsequentantibioticdeescalation
AT stohsericaj implementationofarapidmultiplexpolymerasechainreactionpneumoniapanelandsubsequentantibioticdeescalation
AT marcelinjasminer implementationofarapidmultiplexpolymerasechainreactionpneumoniapanelandsubsequentantibioticdeescalation
AT alexanderbryant implementationofarapidmultiplexpolymerasechainreactionpneumoniapanelandsubsequentantibioticdeescalation
AT watkinsandrewb implementationofarapidmultiplexpolymerasechainreactionpneumoniapanelandsubsequentantibioticdeescalation
AT creagerhannahm implementationofarapidmultiplexpolymerasechainreactionpneumoniapanelandsubsequentantibioticdeescalation
AT bergmanscottj implementationofarapidmultiplexpolymerasechainreactionpneumoniapanelandsubsequentantibioticdeescalation